$10.08
-0.41 (-3.91%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CRBP is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
10 interventional · 4 with posted results
Held by 7 tracked-famous managers (SUSQUEHANNA INTERNATIONAL GROUP, LLP, JANE STREET GROUP, LLC, RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, MARSHALL WACE, LLP, +2 more) · FINRA short interest 9.4 days to cover (settled 2026-07-31) · insider 90d: 2 buys / 3 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| A Randomized, Multicentre, Study to Evaluate CRB-701 Compared to Investigator's Choice Therapy in Previously Treated Oropharyngeal Squamous Cell CarcinomaNCT07768189Objective Response Rate (%)Randomized · Single-masked · Treatment | Phase 3 | Not yet recruiting | Drug: CRB-701, capcitabine, Cetuximab (EGFR inhibitor), Docetaxel | Oropharyngeal Carcinoma (OPC) | 260 | Dec 2027 | ≤ 499 d | 2026-08-17 |
| A Phase 1/2 Study to Investigate CRB-701 in Solid TumorsNCT06265727Part A: To confirm the safety and tolerability and determine MTD and PADR for CRB-701Randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: CRB-701, Anti-PD-1 | Solid Tumor, Adult | 348 | 2027-01-16 | in 150 d | 2026-01-08 |
| First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.NCT06603844Occurance of Dose-limiting toxicitiesNon-randomized · Open-label · Treatment | Phase 1/2 | Recruiting | Drug: CRB-601 monoclonal antibody, Anti-PD-1 monoclonal antibody | Solid Tumor | 156 | 2026-11-01 | in 74 d | 2025-06-03 |
| A 2-part, Phase 1b Clinical Study Designed to Evaluate the Safety, PK, and Efficacy of CRB-913 in Participants With ObesityNCT07310901Part 1: To evaluate the PK of a single dose of CRB-913 - CmaxRandomized · Double-masked · Treatment | Phase 1 | Active, not recruiting | Drug: CRB-913, Placebo | Obese But Otherwise Healthy Participants | 252 | 2026-07-02 | — | 2026-05-29 |
| Trial to Evaluate Efficacy and Safety of Lenabasum in DermatomyositisNCT03813160Efficacy of lenabasum 20 mg BID compared to placebo BID as measured by Total Improvement Score (TIS)Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Lenabasum 20 mg, Lenabasum 5 mg, Placebo | Dermatomyositis | 176 | 2021-03-31actual | — | 2022-08-16 |
| Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic FibrosisNCT03451045results2023-01-18Pulmonary Exacerbation (PEx) Rate Over 28 WeeksRandomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: Lenabasum 20 mg, Lenabasum 5 mg · Other: Placebo | Cystic Fibrosis | 447 | 2020-06-17actual | — | 2023-01-18 |
| Trial to Evaluate Efficacy and Safety of Lenabasum in Diffuse Cutaneous Systemic SclerosisNCT03398837Efficacy of lenabasum compared to placebo for the American College of Rheumatology Combined Response Index in diffuse cutaneous Systemic Sclerosis score.Randomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: Sponsor terminated open-label extension | Drug: Lenabasum 5 mg, Lenabasum 20 mg · Other: Placebo oral capsule | Diffuse Cutaneous Systemic Sclerosis | 365 | 2020-05-27actual | — | 2021-03-29 |
| Safety, Tolerability, and Efficacy of JBT-101 in Subjects With DermatomyositisNCT02466243results2023-01-19Change in Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) From Baseline in Part A.Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor terminated open-label extension. | Drug: JBT-101, Placebo | Dermatomyositis | 22 | Aug 2017actual | — | 2023-01-19 |
| Safety, Tolerability, Pharmacokinetics, and Efficacy of JBT-101 (Lenabasum) in Cystic FibrosisNCT02465450results2018-02-09Number of Participants With Treatment Emergent Adverse Events.Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: JBT-101 (lenabasum) · Other: Placebo | Cystic Fibrosis | 85 | 2016-12-28actual | — | 2018-04-04 |
| Safety, Tolerability, Efficacy, and Pharmacokinetics of JBT-101 in Systemic SclerosisNCT02465437results2018-10-02Number of Participants With Treatment-emergent Adverse Events From Baseline at Day 113Randomized · Double-masked · Treatment | Phase 2 | Terminatedsponsor's stated reason: Sponsor terminated open-label extension | Drug: JBT-101, Placebo, Part B Open-Label Extension | Diffuse Cutaneous Systemic Sclerosis | 42 | Oct 2016actual | — | 2021-04-21 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19